In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 275 of 425

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]	Technology appraisal guidance	TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]	Technology appraisal guidance	14 January 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance	29 July 2026
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]	Technology appraisal guidance	TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]	Technology appraisal guidance	TBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]	Technology appraisal guidance	TBC
Non-invasive skin closure devices for surgical incisions (MT775)	Medical technologies guidance	TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286	Technology appraisal guidance	TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]	Technology appraisal guidance	11 December 2025
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519	Technology appraisal guidance	TBC
Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]	Technology appraisal guidance	11 March 2026
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management	NICE guideline	TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation	Interventional procedures guidance	4 March 2026
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]	Technology appraisal guidance	19 August 2026
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
Optical Coherence Tomography to guide percutaneous coronary intervention	Interventional procedures guidance	TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC

Results per page

10
25
50
All